FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2761567953> ?p ?o ?g. }

• W2761567953 endingPage "18" @default.
• W2761567953 startingPage "6" @default.
• W2761567953 abstract "Background Direct oral anticoagulants ( DOAC s) have been proposed as a more convenient alternative to vitamin K antagonists ( VKA s), which are commonly associated with poor treatment persistence in non‐valvular atrial fibrillation (nv‐ AF ). Methods Using data from the French national health care databases ( Régime Général , 50 million beneficiaries), a cohort study was conducted to compare the 1‐year non‐persistence rates in nv‐ AF patients initiating dabigatran (N=11,141) or rivaroxaban (N=11,126) versus VKA (N=11,998). Treatment discontinuation was defined as a switch between oral anticoagulant ( OAC ) classes or a 60‐day gap with no medication coverage, with the additional criterion of no reimbursement for international normalized ratio monitoring during this gap for VKA patients. Considering death as a competing risk, differences between 1‐year discontinuation rates were used to compare each DOAC versus VKA . The 95% confidence intervals (CIs) were estimated via bootstrapping. Baseline patient characteristics were adjusted using inverse probability of treatment weighting. Subgroup analyses considered DOAC dose at initiation, age, risk of stroke, and bleeding. Results Adjusted 1‐year discontinuation rates were higher for dabigatran than for VKA new users (36.8% vs 30.2%; difference: 6.6% [95% CI , 5.5–7.6]) and for rivaroxaban versus VKA new users (33.4% vs 30.4%; 3.0% [1.9–4.1]). Similar differences were found in all subgroup analyses, except in dabigatran and rivaroxaban patients <75 years (dabigatran vs VKA : 0.3% [−1.4 to 1.8]; rivaroxaban vs VKA : −2.6% [−4.3 to −0.9]) and dabigatran 150 mg new users (−1.1% [−3.1 to 0.7]). Consistent results were obtained when considering both switches between OAC classes and death as competing risks of treatment discontinuation. Conclusion Results from this nationwide cohort study showed high non‐persistence levels with all OAC s and suggest that persistence with both dabigatran and rivaroxaban therapy is not better than persistence with VKA therapy. Hospitalizations for bleeding among non‐persistent patients were unlikely to explain these high non‐persistence rates." @default.
• W2761567953 created "2017-10-20" @default.
• W2761567953 creator A5007909493 @default.
• W2761567953 creator A5010670616 @default.
• W2761567953 creator A5021605461 @default.
• W2761567953 creator A5059157113 @default.
• W2761567953 creator A5082932725 @default.
• W2761567953 date "2017-12-11" @default.
• W2761567953 modified "2023-09-30" @default.
• W2761567953 title "Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases" @default.
• W2761567953 cites W1547546593 @default.
• W2761567953 cites W1567051068 @default.
• W2761567953 cites W1741567663 @default.
• W2761567953 cites W1843312881 @default.
• W2761567953 cites W1913182214 @default.
• W2761567953 cites W1934003446 @default.
• W2761567953 cites W1974546914 @default.
• W2761567953 cites W1975757685 @default.
• W2761567953 cites W1979206887 @default.
• W2761567953 cites W1982173905 @default.
• W2761567953 cites W1986049531 @default.
• W2761567953 cites W2003479746 @default.
• W2761567953 cites W2016722530 @default.
• W2761567953 cites W2030404218 @default.
• W2761567953 cites W2062765161 @default.
• W2761567953 cites W2063844762 @default.
• W2761567953 cites W2066380890 @default.
• W2761567953 cites W2074206824 @default.
• W2761567953 cites W2074627993 @default.
• W2761567953 cites W2076544060 @default.
• W2761567953 cites W2085501100 @default.
• W2761567953 cites W2097854437 @default.
• W2761567953 cites W2106143461 @default.
• W2761567953 cites W2110818436 @default.
• W2761567953 cites W2110901751 @default.
• W2761567953 cites W2121690051 @default.
• W2761567953 cites W2135241452 @default.
• W2761567953 cites W2136489990 @default.
• W2761567953 cites W2147018083 @default.
• W2761567953 cites W2154746519 @default.
• W2761567953 cites W2164643105 @default.
• W2761567953 cites W2169793874 @default.
• W2761567953 cites W2171284718 @default.
• W2761567953 cites W2178817764 @default.
• W2761567953 cites W2206494890 @default.
• W2761567953 cites W2220556496 @default.
• W2761567953 cites W2253985091 @default.
• W2761567953 cites W2264767503 @default.
• W2761567953 cites W2295147099 @default.
• W2761567953 cites W2464204870 @default.
• W2761567953 cites W2504388219 @default.
• W2761567953 cites W2515405935 @default.
• W2761567953 cites W2517582840 @default.
• W2761567953 cites W2524023308 @default.
• W2761567953 cites W2607741304 @default.
• W2761567953 cites W2617556060 @default.
• W2761567953 cites W3004050106 @default.
• W2761567953 cites W784008945 @default.
• W2761567953 doi "https://doi.org/10.1002/phar.2046" @default.
• W2761567953 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29028119" @default.
• W2761567953 hasPublicationYear "2017" @default.
• W2761567953 type Work @default.
• W2761567953 sameAs 2761567953 @default.
• W2761567953 citedByCount "25" @default.
• W2761567953 countsByYear W27615679532018 @default.
• W2761567953 countsByYear W27615679532019 @default.
• W2761567953 countsByYear W27615679532020 @default.
• W2761567953 countsByYear W27615679532021 @default.
• W2761567953 countsByYear W27615679532022 @default.
• W2761567953 countsByYear W27615679532023 @default.
• W2761567953 crossrefType "journal-article" @default.
• W2761567953 hasAuthorship W2761567953A5007909493 @default.
• W2761567953 hasAuthorship W2761567953A5010670616 @default.
• W2761567953 hasAuthorship W2761567953A5021605461 @default.
• W2761567953 hasAuthorship W2761567953A5059157113 @default.
• W2761567953 hasAuthorship W2761567953A5082932725 @default.
• W2761567953 hasConcept C126322002 @default.
• W2761567953 hasConcept C2776301958 @default.
• W2761567953 hasConcept C2776704044 @default.
• W2761567953 hasConcept C2778661090 @default.
• W2761567953 hasConcept C2778715236 @default.
• W2761567953 hasConcept C2778810321 @default.
• W2761567953 hasConcept C2779161974 @default.
• W2761567953 hasConcept C2780638905 @default.
• W2761567953 hasConcept C71924100 @default.
• W2761567953 hasConceptScore W2761567953C126322002 @default.
• W2761567953 hasConceptScore W2761567953C2776301958 @default.
• W2761567953 hasConceptScore W2761567953C2776704044 @default.
• W2761567953 hasConceptScore W2761567953C2778661090 @default.
• W2761567953 hasConceptScore W2761567953C2778715236 @default.
• W2761567953 hasConceptScore W2761567953C2778810321 @default.
• W2761567953 hasConceptScore W2761567953C2779161974 @default.
• W2761567953 hasConceptScore W2761567953C2780638905 @default.
• W2761567953 hasConceptScore W2761567953C71924100 @default.
• W2761567953 hasIssue "1" @default.
• W2761567953 hasLocation W27615679531 @default.
• W2761567953 hasLocation W27615679532 @default.
• W2761567953 hasLocation W27615679533 @default.

• next